GLPG 2222

Drug Profile

GLPG 2222

Alternative Names: GLPG2222

Latest Information Update: 13 Feb 2017

Price : $50

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics; Galapagos NV
  • Developer Galapagos NV
  • Class
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis

Most Recent Events

  • 01 Jan 2017 Phase-II clinical trials in Cystic fibrosis (Monotherapy, Adjunctive treatment) in Belgium (PO) (NCT03045523)
  • 15 Jun 2016 Pharmacokinetics and adverse events data from a phase-I trial in Cystic fibrosis (In volunteers) released by Galapagos
  • 01 May 2016 Galapagos completes phase-I clinical trials in Cystic fibrosis (In volunteers, Monotherapy) in Belgium (PO) (NCT02662452)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top